Craft
Foghorn Therapeutics

Foghorn Therapeutics

Discovery Stage Products

3

Q2, 2020

Revenue

$1.3 M

FY, 2021

Market Capitalization

$332.4 M

2023-01-23

Foghorn Therapeutics Summary

Company summary

Overview
Foghorn Therapeutics is a developer of gene therapies for hematologic cancers and solid tumors. Through its Gene Traffic Control platform, the company studies, identifies, and validates potential drug targets within the chromatin regulatory system.
Type
Public
Status
Active
Founded
2016
HQ
Cambridge, MA, US | view all locations
Website
http://www.foghorntx.com
Cybersecurity rating
ESG rating
30-39 out of 100|View all ESG data
Sectors

Key people

  • Adrian Gottschalk

    Adrian Gottschalk, Chief Executive Officer

  • Samuel Agresta

    Samuel Agresta, Chief Medical Officer

  • Fanny Cavalié

    Fanny Cavalié, Senior Vice President, Business and Operations

  • Steve Bellon

    Steve Bellon, Senior Vice President , Drug Discovery, Vice President, Drug Discovery

Operating MetricsView all

Discovery Stage Products

3

Q2, 2020

IND-Enabling Stage Products

2

Q2, 2020

LocationsView all

2 locations detected

  • Cambridge, MA HQ

    United States

    NE47, 500 Technology Square #700

  • Cambridge, MA

    United States

    100 Binney St #610

Foghorn Therapeutics Financials

Summary financials

Revenue (Q3, 2022)
$6.6M
Net income (Q3, 2022)
($25.8M)
Cash (Q3, 2022)
$87.6M
EBIT (Q3, 2022)
($28.3M)
Enterprise value
$298.0M

Footer menu